A5081118960- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Liver physiology and pathology
- Poisoning and overdose treatments
- Cancer Mechanisms and Therapy
- Cardiac, Anesthesia and Surgical Outcomes
- Mesenchymal stem cell research
- Hepatitis C virus research
- Drug-Induced Hepatotoxicity and Protection
- Neurogenesis and neuroplasticity mechanisms
- Cardiac electrophysiology and arrhythmias
- Bariatric Surgery and Outcomes
- Global Cancer Incidence and Screening
- Clinical practice guidelines implementation
- Nerve injury and regeneration
- Colorectal Cancer Treatments and Studies
- Appendicitis Diagnosis and Management
- Body Contouring and Surgery
- Multiple and Secondary Primary Cancers
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Enhanced Recovery After Surgery
- Colorectal Cancer Surgical Treatments
McMaster University
2019-2024
Juravinski Cancer Centre
2023-2024
Health Sciences North
2019-2021
University of Toronto
2012-2021
Trillium Health Centre
2021
NOSM University
2019-2021
Laurentian University
2019-2021
4098 Background: Advances in systemic therapy for HCC have increased treatment options, including TKIs and immunotherapy combinations. Variables that predict patient outcomes may be helpful personalizing decisions. The aim of this study was to identify predictors short-term death (STD) long-term survival (LTS) patients. Methods: Retrospective review patients with advanced who received a TKI or combinations conducted between Aug 2018 2022 the Canadian provinces British Columbia, Alberta, Nova...
4111 Background: Lenvatinib (LEN) and the combination of atezolizumab with bevacizumab (AB) are widely considered first-line systemic therapies for treatment advanced hepatocellular carcinoma (HCC), but have never been compared directly in a randomized clinical trial. Cross-trial comparisons between IMbrave150 LEAP-002 appear to show similar survival outcomes AB LEN, respectively, while LEN was shorter REFLECT Methods: Patients treated or HCC from August 2018 2022 Canadian provinces British...
For decades, the cornerstone for treatment of advanced urothelial carcinoma (aUC) has consisted platinum-based chemotherapy regimens, such as GC (gemcitabine plus cisplatin/carboplatin) or MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). Thereafter, immune checkpoint inhibitors (ICI) were incorporated into standard care, initially monotherapy in subsequent-line settings more recently maintenance with first-line setting. Recently, development antibody-drug conjugates (ADCs)...
<h3>Background</h3> Timeliness can have a substantial effect on treatment outcomes, prognosis and quality of life for patients with lung cancer. We sought to evaluate changes in wait times non–small cell carcinoma (NSCLC) identify bottlenecks cancer care. <h3>Methods</h3> included who received curative intent or palliative NSCLC, diagnosed through mediastinal staging by thoracic surgeon. Data were collected from 3 cohorts over time periods: before the regionalization care (2005–2007, C1),...
719 Background: Patients with locally advanced rectal cancer (LARC) undergo surgery at 6-8 weeks after neoadjuvant chemoradiation based on standard protocol. However, the optimal time to remains debatable. The goal of this study was identify associations between and additional variables overall survival (OS) recurrence rates in LARC patients. Methods: A retrospective chart review conducted for 80 patients T3 or node positive disease, who have undergone St. Michael’s Hospital from January 1st...